Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q1 FY25 results · Apr–Jun 2024
Glenmark Pharmaceuticals reported revenue from operations of ₹3,244.19 crore (down 4.6% from Q1 FY24) and net profit of ₹340.24 crore (up 96.5% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,244.19 | 3,401.60 | −4.6% | 3,062.95 | +5.9% |
| Other income | 31.49 | 20.87 | +50.9% | 773.16 | −95.9% |
| Total income | 3,275.68 | 3,422.47 | −4.3% | 3,836.12 | −14.6% |
| Profit before tax | 462.33 | 333.41 | +38.7% | 530.83 | −12.9% |
| Net profit for the period | 340.24 | 173.13 | +96.5% | (1,214.27) | Turned profit |
| EPS, basic (₹) | 12.06 | 5.31 | +127.1% | (43.18) | Turned profit |
| Net margin (%) | 10.5 | 5.1 | -39.6 |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,329.54 | 2,144.38 | +8.6% | 2,148.22 | +8.4% |
| Other income | 55.65 | 49.36 | +12.7% | 786.27 | −92.9% |
| Total income | 2,385.18 | 2,193.74 | +8.7% | 2,934.49 | −18.7% |
| Profit before tax | 618.31 | 392.04 | +57.7% | 6,294.85 | −90.2% |
| Net profit for the period | 453.73 | 271.66 | +67.0% | 4,613.69 | −90.2% |
| EPS, basic (₹) | 16.08 | 9.63 | +67.0% | 163.50 | −90.2% |
| Net margin (%) | 19.5 | 12.7 | 214.8 |
Consolidated
- Filed with BSE
- 16 Aug 2024, 17:56 IST
- Board meeting
- 14 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 16 Aug 2024, 17:56 IST
- Board meeting
- 14 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE